{"organizations": [], "uuid": "e99ccbe1d21d64f9e56addb3e7fa3fc5aeef435a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cellect-biotechnology-announces-cl/brief-cellect-biotechnology-announces-clinical-results-idUSFWN1OZ0MX", "country": "US", "domain_rank": 408, "title": "BRIEF-Cellect Biotechnology Announces Clinical Results", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T15:11:00.000+02:00", "replies_count": 0, "uuid": "e99ccbe1d21d64f9e56addb3e7fa3fc5aeef435a"}, "author": "", "url": "https://www.reuters.com/article/brief-cellect-biotechnology-announces-cl/brief-cellect-biotechnology-announces-clinical-results-idUSFWN1OZ0MX", "ord_in_thread": 0, "title": "BRIEF-Cellect Biotechnology Announces Clinical Results", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "cellect biotechnology ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 1:12 PM / Updated 10 minutes ago BRIEF-Cellect Biotechnology Announces Clinical Results Reuters Staff 1 Min Read \nJan 4 (Reuters) - Cellect Biotechnology Ltd: \n* CELLECT BIOTECHNOLOGY - ‍COMPLETED TRANSPLANTATION OF FIRST GROUP OF 3 PATIENTS USING CELLECT‘S APOGRAFT TECHNOLOGY IN CO‘S PHASE I/II CLINICAL TRIAL​ \n* CELLECT BIOTECHNOLOGY-‍AFTER 1 MONTH FOLLOW-UP, ALL 3 PATIENTS DEMONSTRATED ACCEPTANCE OF STEM CELL TRANSPLANT WITH NO ADVERSE EVENTS RELATED TO STUDY​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T15:11:00.000+02:00", "crawled": "2018-01-04T15:27:59.014+02:00", "highlightTitle": ""}